RT Journal Article
SR Electronic
T1 Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.05.20169201
DO 10.1101/2020.08.05.20169201
A1 Ha-Lim Jeon
A1 Jun Soo Kwon
A1 So-Hee Park
A1 Ju-Young Shin
YR 2020
UL http://medrxiv.org/content/early/2020/08/07/2020.08.05.20169201.abstract
AB Background No epidemiological data exists for the association between mental disorders and the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) severity.Aims To evaluate the association between mental disorders and the risk of SARS-CoV-2 infection and severe outcomes following COVID-19.Methods We performed a cohort study using the Korean COVID-19 patient database based on the national health insurance data. Each patient with a mental or behavioral disorder (diagnosed during six months prior to the first SARS-CoV-2 test) was matched by age, sex, and Charlson comorbidity index with up to four patients without mental disorders. SARS-CoV-2 positivity risk and risk of death or severe events (intensive care unit admission, use of mechanical ventilation, and acute respiratory distress syndrome) post-infection were calculated using conditional logistic regression analysis.Results Among 230,565 patients tested for SARS-CoV-2, 33,653 (14.6%) had mental disorders, 928/33,653 (2.76%) tested positive, and 56/928 (6.03%) died. In multivariate analysis with the matched cohort, there was no association between mental disorders and SARS-CoV-2 positivity risk (odds ratio [OR], 1.02; 95% confidence interval [CI], 0.92-1.12); however, a higher risk was associated with schizophrenia-related disorders (OR, 1.36; 95% CI, 1.02-1.81). Among confirmed cases, mortality risk significantly increased in patients with mental disorders (OR, 1.84, 95% CI, 1.07-3.15).Conclusion Mental disorders are likely contributing factors of mortality following COVID-19. Although the infection risk did not increase in overall mental disorders, patients with schizophrenia-related disorders were more vulnerable to the infection.Competing Interest StatementJYS has received research grants from the Ministry of Food and Drug Safety, Ministry of Health and Welfare, the National Research Foundation of Republic of Korea, and pharmaceutical companies including Amgen, Pfizer, Hoffmann-La Roche, Dong-A ST, and Yungjin; no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis study received no specific grant from any funding agency, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the Sungkyunkwan University in Korea (IRB number: SKKU-2020-05-012).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from Health Insurance Review & Assessment service (HIRA) in South Korea. Restrictions apply to the availability of these data, which were used under licence for this study. Data access is available at https://hira-covid19.net/ with the permission of HIRA.